The modern spectrum of rhabdomyolysis: Drug toxicity revealed by creatine kinase screening

Current Drug Safety

Volumn 4, Issue 3, 2009, Pages 181-187

  Linares, Leslie A ^a   Golomb, Beatrice A ^b   Jaojoco, Joyce A ^a   Sikand, Harminder ^a   Phillips, Paul S ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATORVASTATIN; BENZODIAZEPINE; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OXYCODONE; QUETIAPINE; RECREATIONAL DRUG; SIMVASTATIN; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ADULT; ALCOHOL ABUSE; ARTICLE; COMPRESSION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DRUG INTOXICATION; DRUG OVERDOSE; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE INJURY; MYOGLOBINURIA; PRIORITY JOURNAL; REFERENCE VALUE; RHABDOMYOLYSIS; SEIZURE; SHOCK; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; ENZYME ASSAY; MIDDLE AGED; MULTICENTER STUDY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; CALIFORNIA; CLINICAL ENZYME TESTS; CREATINE KINASE; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, ACUTE; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; RISK FACTORS; UP-REGULATION;

EID: 73349103163     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488609789007010     Document Type: Article

References (63)

1. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine 1982; 61: 141-52.
2. Thompson P, Clarkson P, Rosenson R. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97(Suppl): 69C-76C.
3. Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis-an overview for clinicians. Crit Care 2005; 9: 158-69.
4. Poels PJ, Gabreëls. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993; 95: 175-92.
5. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377-85.
6. Ward, MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Int Med 1988; 148: 1553-7.
7. Okie S. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 2005; 352: 1173-6.
8. Klein DF, O'Brien CP. Improving detection of adverse effects of marketed drugs. JAMA 2007; 298: 333-4.
9. Patient Origin and Market Share Reports. California Office of Stateweide Health Planning and Development: Sacramento 2005.
10. Havranek JM, Wolfsen AR, Warnke GA, et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006; 119: 285-6.
11. Zhou S, Chan SY, Cher GB, et al, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
12. Dale KM, Coleman CI, Henyan NN, et al. Does More Aggressive Statin Therapy Increase Muscle and Liver Risk? Atlanta, GA: 55th Annual Scientific Sessions of the American College of Cardiology. Atlanta, GA 2006.
13. Golomb B, Yang E, Denenberg J, et al. Statin-associated muscle adverse effects. Circulation 2003: 7028-9.
14. Scranton RE, Cantillon C, Gagnon D, et al. Occurrences of rhabdomyolysis or myositis among statin users in a Veteran Affairs population (abstract from presentation at the AHA Council on Epidemiology and Prevention meeting in March 2004, San Francisco). Circulation 2004; 6: 154.
15. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 2: 253-60.
16. Aguilar GMD, Garmendia LJR, Cuende MJI, et al. [Rhabdomyolysis in neuroleptics: are we talking of neuroleptic malignant syndrome?]. Aten Primaria 2003; 32: 66-7.
17. Baumgart U, Schmid R, Spiessl H. Olanzapine-induced acute rhabdomyolysis-a case report. Pharmacopsychiatry 2005; 38: 36-7.
18. Burkhardt C, Kelly JP, Lim YH, et al. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993; 33: 512-7.
19. Giner V, Munoz R, Redon J. Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 2002; 251: 177-8.
20. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996; 15: 395-405.
21. Pezza M, Busiello L, Palmese S, et al. Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment. Minerva Anestesiol 2003; 69: 591-6.
22. Rosebraugh CJ, Flockart DA, Yauda SU, et al. Olanzapine-induced rhabdomyolysis. Ann Pharmacother 2001; 35: 1020-3.
23. Scelsa SN, Simpson DM, McQuistion HL, et al. Clozapine-induced myotoxicity in patient with chronic psychotic disorders. Neurology 1996; 47: 1518-23.
24. Shuster J. Olanzapine and rhabdomyolysis. Nursing 2000; 30: 87.
25. Sikand H, Jaojoco J, Linares L, et al. Atypical antipsychotic drugs, dementia, and risk of death. JAMA 2006; 295: 495.
26. Smith RP, Puckett BN, Crawford J, et al. Quetiapine overdose and severe rhabdomyolysis. J Clin Psychopharmacol 2004; 24: 343.
27. Waring WS, Wrate J, Bateman DN. Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 2006; 25: 735-40.
28. Webber MA, Mahmud W, Lightfoot JD, et al. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 2004; 18: 432-4.
29. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002; 159: 1435.
30. Zink M, Knopf U, Argiriou S, et al. A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. J Clin Psychiatry 2006; 67: 835.
31. Himmerich H, Ehrlinger M, Hackenberg M, et al. Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. J Clin Psychopharmacol 2006; 26: 676-7.
32. Allison R, Bedsole L. The other medical causes of rhabdomyolysis. Am J Med Sci 2003; 326: 79-88.
33. Löfberg M, Jänkälä H, Paetau A, et al. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 1998; 98: 268-75.
34. Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician 2002; 65: 907-12.
35. Phillips PS, Phillips CT, Sullivan MJ, et al. Statin myotoxicity is associated with changes in cardiopulmonary function. Atherosclerosis 2004; 177: 183-8.
36. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 2: 153-62.
37. Jaojoco J, Phillips P, Sikand H. Defining Rhabdomyolysis as an adverse drug event trigger for medication toxicity. St Louis, MO: Poster # 9360 at American Colleges of Clinical Pharmacy 2006.
38. Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9.
39. Hill CF, Schwartz LM, Thompson PD, et al. Effects Of Statin Treatment And Supplemental Co Q10 On C2C12 Myotubes: 2436. Med Sci Sports Exercise 2005; 37: 466-7.
40. Carey EC, Walter LC, Lindquist K, et al. Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med 2007; 19: 1027-33.
41. Chuang KH, Covinsky KE, Sands LP, et al. Diagnosis-related group-adjusted hospital costs are higher in older medical patients with lower functional status. J Am Geriatr Soc 2003; 51: 1729-34.
42. Covinsky KE, Justice AC, Rosenthal GE, et al. Measuring prognosis and case mix in hospitalized elders. The importance of functional status. J Gen Intern Med 1997; 12: 203-8.
43. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998; 279: 585-92.
44. Holahan J, Dubay LC, Kenney G, et al. Should Medicare compensate hospitals for administratively necessary days? Milbank Q 1989; 67: 137-67.
45. Inouye SK, Peduzzi PN, Robison JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998; 279: 1187-93.
46. Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001; 285: 2987-94.
47. De Meijer AR, Fikkrs BG, de Keijzer MH, et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intens Care Med 2003; 29: 1121-5.
48. Fernandez WG, Hung O, Bruno GR, et al. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rhabdomyolysis. Am J Emerg Med 2005; 23: 1-7.
49. Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004; 56: 1191-6.
50. Clarkson PM. Exertional rhabdomyolysis and acute renal failure in marathon runners. Sports Med 2007; 37: 361-3.
51. Clarkson PM, Kearns AK, Rouzier P, et al. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006; 38: 623-7.
52. Lin AC, Lin CM, Wang TL, et al. Rhabdomyolysis in 199 students after repetitive exercise. Br J Sports Med 2005; 39: 3.
53. Harper J. Rhabdomyolysis and myoglobinuric renal failure. Crit Care Nurs 1990; 10: 32-6.
54. Graham DJ, Waller PC, Kurz X. A view from regulatory agencies. In: Strom BL, Ed. Pharmacoepidemiology. 3rd ed. New York, NY: John Wiley & Sons 2000; pp. 109-24.
55. Scott HD, Rosenbaum SE, Waters WJ, et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311-6.
56. Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824-6.
57. Ramon-Blanco J, Zabalza M, Salcedo J, et al. Rhabdmyolysis of infectious and noninfectious causes. South Med J 2002; 95: 542-4.
58. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007; 16: 1275-84.
59. Cornish PL, Knowles SR, Marchesano R, et al. Unintended medication discrepancies at the time of hospital admission. Arch Intern Med 2005; 165: 424-9.
60. Gleason KM, Groszek JM, Sullivan C, et al. Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients. Am J Health Syst Pharm 2004; 61: 1689-95.
61. Vira T, Colquhoun M, Etchells E. Reconcilable differences: correcting medication errors at hospital admission and discharge. Qual Saf Health Care 2006; 15: 122-6.
62. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
63. Veenstra J, Smit WM, Krediet RT, et al. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant 1994; 9: 637-41.